← All organizations
Highest phase reached
Phase 2
First clinical trial
Oct 1, 2012Last known activity
Sep 30, 2018
Timeline
2000s
- Jun 1, 2004
California Institute for Regenerative Medicine— Founded
Drugs by trial phase (17 distinct, 11 trials)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (14 own, 0 via acquisition)
- cfi-400945
- tacrolimus
- amg-191
- pentostatin
- mycophenolate
- cyclophosphamide
- Anti-thymocyte Globulin (Rabbit)
- allogeneic adipose derived mesenchymal stem cell
- autologous cd34+ cells
- llp2a-alendronate
- cns10-npc-gdnf
- betaas3-fb vector transduced bm cd34+ cells
- allogeneic blood cells
- cd4+ t-cell-depleted haploidentical hematopoietic cells
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Anemia, Sickle Cell
- Bone Diseases, Metabolic
- Carcinoma, Non-Small-Cell Lung
- Familial Primary Pulmonary Hypertension
- Granuloma
- Granulomatous Disease, Chronic
- Hemoglobinopathies
- Hypertension
- Immunologic Deficiency Syndromes
- Infarction
- Motor Neuron Disease
- Myocardial Infarction
- Neoplasms
- Osteonecrosis
- Osteoporosis
- Sarcoma
- Sclerosis
- Severe Combined Immunodeficiency
- Thalassemia
- Ventricular Dysfunction
Recent trials (11)
- NCT03249831CollaboratorPhase 1Sep 30, 2018
- NCT03145298CollaboratorPhase 1Jul 1, 2017
- NCT02943850CollaboratorPhase 1Apr 1, 2017
- NCT03292445CollaboratorEarly Phase 1Feb 14, 2017
- NCT02999984CollaboratorPhase 1/Phase 2Dec 1, 2016
- NCT03197623CollaboratorPhase 1Oct 14, 2016
- NCT02963064CollaboratorPhase 1Aug 1, 2016
- NCT02234934CollaboratorPhase 1/Phase 2Jan 1, 2015
- NCT02247843CollaboratorPhase 1Jul 1, 2014
- NCT01954316CollaboratorPhase 1Mar 1, 2014
- NCT01458405CollaboratorPhase 1/Phase 2Oct 1, 2012
Details
- Founded
- San Francisco, CA, US Jun 1, 2004
- Last known activity
- Sep 30, 2018